These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35166264)

  • 1. A Nationwide Prospective Clinical Trial on Active Surveillance in Patients With Non-intraabdominal Desmoid-type Fibromatosis: The GRAFITI Trial.
    Schut AW; Timbergen MJM; van Broekhoven DLM; van Dalen T; van Houdt WJ; Bonenkamp JJ; Sleijfer S; Grunhagen DJ; Verhoef C
    Ann Surg; 2023 Apr; 277(4):689-696. PubMed ID: 35166264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Prospective Observational Study of Active Surveillance in Primary Desmoid Fibromatosis.
    Colombo C; Fiore M; Grignani G; Tolomeo F; Merlini A; Palassini E; Collini P; Stacchiotti S; Casali PG; Perrone F; Mariani L; Gronchi A
    Clin Cancer Res; 2022 Sep; 28(18):4027-4032. PubMed ID: 35247923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Prognostic Role of β-Catenin Mutations in Desmoid-type Fibromatosis Undergoing Resection Only: A Meta-analysis of Individual Patient Data.
    Timbergen MJM; Colombo C; Renckens M; Kim HS; Rosmalen JV; Salas S; Mullen JT; Colombo P; Nishida Y; Wiemer EAC; Verhoef C; Sleijfer S; Gronchi A; Grünhagen DJ
    Ann Surg; 2021 Jun; 273(6):1094-1101. PubMed ID: 31804402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wnt targets genes are not differentially expressed in desmoid tumors bearing different activating β-catenin mutations.
    Timbergen MJM; Janssen ML; Verhoef C; Grünhagen DJ; Chibon F; Smid M; Sleijfer S; Wiemer EAC
    Eur J Surg Oncol; 2019 Apr; 45(4):691-698. PubMed ID: 30528042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related Quality of Life of Patients With Non-Intra-abdominal Desmoid-Type Fibromatosis During Active Surveillance: Results of a Prospective Observational Study.
    Schut AW; Timbergen MJM; Nasserinejad K; van Dalen T; van Houdt WJ; Bonenkamp JJ; Sleijfer S; Grünhagen DJ; Verhoef C; Husson O;
    Ann Surg; 2023 Jun; 277(6):877-883. PubMed ID: 36727954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tailored Beta-catenin mutational approach in extra-abdominal sporadic desmoid tumor patients without therapeutic intervention.
    van Broekhoven DL; Grünhagenl DJ; van Dalen T; van Coevorden F; Bonenkamp HJ; Been LB; Bemelmans MH; Dijkstra SD; Colombo C; Gronchi A; Verhoef C
    BMC Cancer; 2016 Aug; 16(1):686. PubMed ID: 27565718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the Addition of Mutations of CTNNB1 S45F to Clinical Factors Allow Prediction of Local Recurrence in Patients With a Desmoid Tumor? A Local Recurrence Risk Model.
    Pinto FFE; Mello CAL; Nakagawa SA; Chung WT; Torrezan GT; Barros BDF; Cunha IW; Calsavara VF; Carraro DM; Lopes A
    Clin Orthop Relat Res; 2023 Oct; 481(10):1978-1989. PubMed ID: 37104792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study.
    Colombo C; Miceli R; Lazar AJ; Perrone F; Pollock RE; Le Cesne A; Hartgrink HH; Cleton-Jansen AM; Domont J; Bovée JV; Bonvalot S; Lev D; Gronchi A
    Cancer; 2013 Oct; 119(20):3696-702. PubMed ID: 23913621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentially Methylated Regions in Desmoid-Type Fibromatosis: A Comparison Between CTNNB1 S45F and T41A Tumors.
    Timbergen MJM; Boers R; Vriends ALM; Boers J; van IJcken WFJ; Lavrijsen M; Grünhagen DJ; Verhoef C; Sleijfer S; Smits R; Gribnau J; Wiemer EAC
    Front Oncol; 2020; 10():565031. PubMed ID: 33194643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential diagnosis and mutation stratification of desmoid-type fibromatosis on MRI using radiomics.
    Timbergen MJM; Starmans MPA; Padmos GA; Grünhagen DJ; van Leenders GJLH; Hanff DF; Verhoef C; Niessen WJ; Sleijfer S; Klein S; Visser JJ
    Eur J Radiol; 2020 Oct; 131():109266. PubMed ID: 32971431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of Prognostic Value of CTNNB1 Mutation Profile in Desmoid-Type Fibromatosis.
    Penel N; Bonvalot S; Bimbai AM; Meurgey A; Le Loarer F; Salas S; Piperno-Neumann S; Chevreau C; Boudou-Rouquette P; Dubray-Longeras P; Kurtz JE; Guillemet C; Bompas E; Italiano A; Le Cesne A; Orbach D; Thery J; Le Deley MC; Blay JY; Mir O
    Clin Cancer Res; 2022 Sep; 28(18):4105-4111. PubMed ID: 35294527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01).
    Kasper B; Gruenwald V; Reichardt P; Bauer S; Hohenberger P; Haller F
    Ann Surg Oncol; 2016 Jun; 23(6):1924-7. PubMed ID: 26861905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study.
    Hamada S; Futamura N; Ikuta K; Urakawa H; Kozawa E; Ishiguro N; Nishida Y
    PLoS One; 2014; 9(5):e96391. PubMed ID: 24788118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Nationwide Prospective Clinical Trial on Active Surveillance in Patients With Non-intraabdominal Desmoid-type Fibromatosis: The GRAFITI Trial: Erratum.
    Ann Surg; 2023 Oct; 278(4):e911. PubMed ID: 37678388
    [No Abstract]   [Full Text] [Related]  

  • 15. Frequent CTNNB1 p.S45 Mutations and Aggressive Clinical Behavior in Neuromuscular Choristoma-Associated Fibromatosis.
    Carter JM; Maldonado AA; Howe BM; Okuno S; Spinner RJ
    Neurosurgery; 2021 Mar; 88(4):804-811. PubMed ID: 33442732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical results of active surveillance for extra-abdominal desmoid-type fibromatosis.
    Sakai T; Nishida Y; Ito K; Ikuta K; Urakawa H; Koike H; Imagama S
    Cancer Med; 2023 Mar; 12(5):5245-5254. PubMed ID: 36210645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis.
    van Broekhoven DL; Verhoef C; Grünhagen DJ; van Gorp JM; den Bakker MA; Hinrichs JW; de Voijs CM; van Dalen T
    Ann Surg Oncol; 2015 May; 22(5):1464-70. PubMed ID: 25341748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel pathogenic alterations in pediatric and adult desmoid-type fibromatosis - A systematic analysis of 204 cases.
    Trautmann M; Rehkämper J; Gevensleben H; Becker J; Wardelmann E; Hartmann W; Grünewald I; Huss S
    Sci Rep; 2020 Feb; 10(1):3368. PubMed ID: 32099073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. β-Catenin mutation status and outcomes in sporadic desmoid tumors.
    Mullen JT; DeLaney TF; Rosenberg AE; Le L; Iafrate AJ; Kobayashi W; Szymonifka J; Yeap BY; Chen YL; Harmon DC; Choy E; Yoon SS; Raskin KA; Hornicek FJ; Nielsen GP
    Oncologist; 2013; 18(9):1043-9. PubMed ID: 23960186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term Outcomes of Oral Vinorelbine in Advanced, Progressive Desmoid Fibromatosis and Influence of
    Mir O; Honoré C; Chamseddine AN; Dômont J; Dumont SN; Cavalcanti A; Faron M; Rimareix F; Haddag-Miliani L; Le Péchoux C; Levy A; Court C; Briand S; Fadel E; Mercier O; Bayle A; Brunet A; Ngo C; Rouleau E; Adam J; Le Cesne A
    Clin Cancer Res; 2020 Dec; 26(23):6277-6283. PubMed ID: 32873570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.